United Therapeutics Corporation (UTHR)

235,95 -1,05 (-0,44%) Al cierre: 04:00PM EDT

United Therapeutics Corporation

1000 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
https://www.unither.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 1168

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.	Founder, Chairman & CEO	5,32M	56,15M	1955
Mr. Michael I. Benkowitz	President & COO	2,83M	7,83M	1972
Mr. James C. Edgemond	CFO & Treasurer	2,01M	1,49M	1968
Mr. Paul A. Mahon J.D.	Executive VP, General Counsel & Corporate Secretary	2,31M	13,2M	1964
Mr. Dewey Steadman C.F.A.	Head of Investor Relations	N/A	N/A	N/A
Ms. Holly Hobson	Associate Vice President of Human Resources	N/A	N/A	N/A
Kevin T. Gray	Senior Vice President of Strategic Operations & Logistics	N/A	N/A	N/A
Mr. Patrick Poisson	Executive VP of Technical Operations	N/A	N/A	1968
Dr. Leigh Peterson	Executive Vice President of Product Development & Xenotransplantation	N/A	N/A	N/A
Mr. Gil Golden	Senior VP & Chief Medical Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Gobierno corporativo

El ISS Governance QualityScore de United Therapeutics Corporation, a día 1 de abril de 2024, es 2. Las puntuaciones base son Auditoría: 1; Tablero: 5; Derechos de los accionistas: 3; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.